- Home
- BIIB vs EL Comparison
BIIB vs EL Comparison
Compare BIIB & EL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- EL
- Stock Information
- Founded
- BIIB 1978
- EL 1946
- Country
- BIIB United States
- EL United States
- Employees
- BIIB N/A
- EL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- EL Package Goods/Cosmetics
- Sector
- BIIB Health Care
- EL Consumer Discretionary
- Exchange
- BIIB Nasdaq
- EL Nasdaq
- Market Cap
- BIIB 25.1B
- EL 25.1B
- IPO Year
- BIIB 1991
- EL 1995
- Fundamental
- Price
- BIIB $160.85
- EL $77.48
- Analyst Decision
- BIIB Buy
- EL Hold
- Analyst Count
- BIIB 25
- EL 21
- Target Price
- BIIB $258.57
- EL $94.00
- AVG Volume (30 Days)
- BIIB 1.7M
- EL 5.3M
- Earning Date
- BIIB 10-30-2024
- EL 10-31-2024
- Dividend Yield
- BIIB N/A
- EL 1.81%
- EPS Growth
- BIIB 10.05
- EL N/A
- EPS
- BIIB 11.06
- EL 0.56
- Revenue
- BIIB $9,607,500,000.00
- EL $15,451,000,000.00
- Revenue This Year
- BIIB N/A
- EL N/A
- Revenue Next Year
- BIIB N/A
- EL $3.99
- P/E Ratio
- BIIB $14.54
- EL $137.90
- Revenue Growth
- BIIB N/A
- EL N/A
- 52 Week Low
- BIIB $153.62
- EL $62.29
- 52 Week High
- BIIB $268.30
- EL $159.75
- Technical
- Relative Strength Index (RSI)
- BIIB 37.71
- EL 59.00
- Support Level
- BIIB $158.44
- EL $71.51
- Resistance Level
- BIIB $165.29
- EL $76.42
- Average True Range (ATR)
- BIIB 4.09
- EL 2.42
- MACD
- BIIB 1.04
- EL 2.18
- Stochastic Oscillator
- BIIB 32.51
- EL 98.75
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About EL Estee Lauder Companies Inc. (The)
Estee Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estee Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estee Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.